Edition:
United States

GlycoMimetics Inc (GLYC.OQ)

GLYC.OQ on NASDAQ Stock Exchange Global Market

13.25USD
23 May 2017
Change (% chg)

$2.24 (+20.35%)
Prev Close
$11.01
Open
$11.00
Day's High
$14.29
Day's Low
$10.27
Volume
2,695,198
Avg. Vol
209,479
52-wk High
$14.63
52-wk Low
$3.83

GLYC.OQ

Chart for GLYC.OQ

About

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment... (more)

Overall

Beta: 2.80
Market Cap(Mil.): $271.29
Shares Outstanding(Mil.): 24.64
Dividend: --
Yield (%): --

Financials

  GLYC.OQ Industry Sector
P/E (TTM): -- 139.31 17.29
EPS (TTM): -1.45 -- --
ROI: -95.14 2.29 -5.84
ROE: -96.58 0.06 -5.23

BRIEF-Glycomimetics announces proposed public offering of common stock

* Glycomimetics announces proposed public offering of common stock

May 22 2017

BRIEF-Glycomimetics reports supportive biomarker data from early-stage trial of GMI-1271

* GlycoMimetics announces high overall response rates, low induction mortality, promising initial survival outcomes, and supportive biomarker data from phase 1/2 trial of GMI-1271 in AML Source text for Eikon: Further company coverage:

May 18 2017

BRIEF-Glycomimetics reports qtrly net loss per share of $0.34

* Glycomimetics reports program updates and first quarter 2017 results

May 08 2017

BRIEF-Glycomimetics Q4 loss per share $0.36

* Glycomimetics reports fourth quarter and year-end 2016 results

Mar 01 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $127.52 +0.26
Novartis AG (NOVN.S) CHF79.05 --
Pfizer Inc. (PFE.N) $32.14 +0.02
Merck & Co., Inc. (MRK.N) $64.55 +0.51
Roche Holding Ltd. (ROG.S) CHF267.90 --
Roche Holding Ltd. (RO.S) CHF267.25 --
Bayer AG (BAYGn.DE) €118.05 --
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates